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Hyperimmunoglobulin E syndrome (HIES, Job's Syndrome) is a
rare primary immunodeﬁciency disease characterized by a clinical
triad of recurrent staphylococcal abscesses, pneumonia, and pneu-
matoceles, with a tendency for recurrent pyogenic infections and
elevation of serum immunoglobulin E (IgE) levels.1
A 12-year-old girl presented with ﬂexural eczema and intense
pruritus. The symptoms started when she was 2 months old. She
also suffered from mental motor retardation and frequent upper
respiratory tract infections. Physical examination revealed coarse
facial structure, deep-set eyes, a prominent forehead, prognathism,
thick lower lip and auricles, a wide nose, increased interalar dis-
tance, and postural abnormality. She had eczema plaques on both
sides of her neck, bilateral antecubital fossa, and popliteal fossa
(Figure 1). Pruritic papules were seen on the dorsum of the hands,
extensor side of ankles, and lumbar region. She had a pronounced
high IgE level (3800 IU/mL) and positive reactions to house dust
mites, dog dander, and banana in a prick test. Based on the clinical
and laboratory ﬁndings, HIES was diagnosed and the HIES score
was 28. Treatment with omalizumab was considered as an option,
given the resistant nature of the disease in this patient who had
even previously received interferon treatment without beneﬁt. A
treatment schedule of 300 mg/mo omalizumab injections gave no
beneﬁt, and after the ﬁfth dose, the schedule was changed to
300 mg every other week, which provided relief of the pruritus
and skin lesions. After the second injection of 300 mg omalizumab
every other week, the Scoring Atopic Dermatitis scores decreased
from 42 to 22, and total IgE values decreased to 1376 IU/mL
(Figure 2).
Autosomal dominant and sporadic cases of HIES are caused by
mutations in the signal transducer and activator of transcription-
3 gene (STAT3) on chromosome 17q21, whereas a null mutation
in tyrosine kinase 2 (TK-2) is responsible for autosomal recessive
cases.2,3 STAT-3 regulates cytokines responsible for Th17 cell differ-
entiation and is important in the inﬂammatory response to bacte-
rial and fungal infections.2 In addition, TK-2 plays a role in innate
and adaptive immune systems.3 Al Khatib et al2 reported that
both STAT3 mutation-positive and STAT3 mutation-negative HIES
exhibited a profound deﬁcit in Th17 differentiation. Considering
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HIES.2 Imbalance between Th1 and Th2 cells is caused by increased
IgE values. High IgE values suppress Th1 cells, which produce inter-
feron-g, IL-12, and activate suppressor Th2 cells.
Intravenous Ig, cyclosporine-A, plasmapheresis, and interferon-
g are reported to be successful in individual cases.4
Omalizumab acts by lowering free IgE concentration in the
blood and interstitial spaces and down regulates high afﬁnity IgE
receptors (FcƐRI) on basophils, mast cells, and dendritic cells.5
Omalizumab has been successfully used for the treatment of
various atopic diseases related to elevated IgE levels.5 We found
three cases of patients with HIES in literature whose skin lesions
improved with omalizumab treatment.4,6,7 The ﬁrst case was a
26-year-old woman with asthma and hepatitis C infection. One
month after treatment with subcutaneous omalizumab 450 mg/2
wk, her asthma and skin lesions remarkably improved. She
remained in remission for 6 months after cessation of treatment.6
In the second case, one month of treatment with subcutaneousFigure 1 Erythematous, excoriated plaques on bilateral popliteal fossas (before omali-
zumab treatment).
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Figure 2 After omalizumab treatment. Only postlesional hyperpigmentated patches
are seen on popliteal fossas.
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skin lesions.4 The third case received three injections of monthly
subcutaneous omalizumab 375 mg/2 wk and no active eczematous
skin lesions and pruritus were found after 3 months.7
The mechanism of action of omalizumab in HIES could be
related to its binding ability of free IgE in blood and down regula-
tion of FcƐRI on basophils, mast cells, and dendritic cells. Omalizu-
mab also down regulates CD23 (FcƐRII) on B cells and down
regulates B lymphoblasts and memory B cells that express IgE,
which may cause a reduction in IgE-secreting plasma cells.5 Conse-
quently, these phenomena lead to the inhibition of allergens to acti-
vate basophils and mast cells, which in turn prevent the release of
inﬂammatory mediators and cytokines.
Our patient had recalcitrant eczema and high total IgE concen-
trations despite interferon, topical and systemic corticosteroid
treatments. Due to recalcitrant lesions and to avoid the side effects
associated with long-term use of corticosteroids, we decided to use
omalizumab. First, we used omalizumab at a dose of 300 mg/mo
without effect; then, we increased the dose to 300 mg every other
week, which provided relief of the pruritus and skin lesions. How-
ever, prospective studies and long-term follow-up are required to
conﬁrm the efﬁcacy of omalizumab in HIES.Pırıl Etikan Akbas¸*, Emek Kocatürk
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